The Complexities of Sepsis-Induced Cardiomyopathy: A Clinical Case and Review of Inflammatory Pathways and Potential Therapeutic Targets.

Sepsis-induced cardiomyopathy (SICM) is a life-threatening complication of sepsis characterized by myocardial dysfunction. SICM significantly increases mortality rates in sepsis. Despite its clinical relevance, SICM lacks a unified definition and standardized diagnostic criteria, complicating early identification and treatment. The pathophysiology of SICM is complex and involves a combination of inflammatory mediators, oxidative stress, mitochondrial dysfunction, and dysregulated autonomic responses. Cardiac biomarkers such as B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide, and troponins provide valuable prognostic insights but lack specificity for SICM diagnosis. This article presents the case of a 69-year-old woman who experienced rapid left ventricular dysfunction, initially misattributed to acute coronary syndrome but ultimately diagnosed as SICM. Her condition improved significantly after several days of supportive care, with full recovery of left ventricular function, highlighting the reversible nature of SICM. This article discusses the underlying pathophysiological mechanisms behind SICM, the utility of cardiac biomarkers, and potential therapies addressing specific molecular pathways. Current management of SICM primarily emphasizes supportive care and hemodynamic stabilization. Further research is essential to develop more precise diagnostic tools and effective treatments for this complex and underrecognized condition. Addressing these gaps could significantly reduce treatment delays and improve patient outcomes.